Theralase Technologies Inc. announced a non-brokered private placement to issue 1,840,000 units at an issue price of CAD 0.25 for the gross proceeds of CAD 460,000 on September 7, 2023. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of CAD 0.35per share for a period of 24 months following the date of issuance. All securities issued under the offering will be subject to a four-month-and-one-day hold period from the closing date under applicable Canadian securities laws, which expires on January 8, 2023. The offering is subject to receipt of final acceptance from the TSX Venture Exchange.

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement. The transaction included participation from 11 placees including existing insider involvement of one insider for 424,000.